Everybody is different and everybody’s needs are different. This makes it difficult when determining the best diet, movement, and lifestyle plan for yourself. What works for one of us will not necessarily work for someone else. This is why we are such strong advocates for things like The InsideTracker platform.
Lingo by Abbott
Abbott, a medical device & technology company, has created an innovative biofeedback wearable sensor to measure glucose, lactate, alcohol, and ketone levels. This is not the same as super accurate blood test measuring bio-markers, but is sort of a consumer version of the continuous glucose monitors used by prescription on diabetes. Abbott’s new Lingo biosensor is not meant for medical use and is intended for athletes and users who want to optimize their health. This device is where the medical field meets the wellness field.
Abbott CEO Robert Ford explains that the benefit of understanding one’s glucose levels is “key to a broad range of health benefits, from weight management to better energy and sleep.” Understanding our ketone levels can tell us when we are in ketosis which can aid in weight management, diet, and, for some people, monitoring their ketone levels helps in the prevention or treatment cancer. Understanding lactate levels will allow users to see how much lactic acid has built up in their muscles during a workout which will allow them to know how much recovery time they need before their next workout. Understanding alcohol levels will not only help you understand how much R & R you may need following a night of drinking, but it may also help reduce incidences of drunk driving as users will be able to see where their levels are and if they are under the legal limit.
Take the guesswork out of optimizing your health
A device like this also gives us the personal responsibility to take control of one part of our health. Once you know how your body reacts to the macros you are eating, you have the choice to move towards health or away from it.
Abbott expects to be launching the biosensors at the end of 2022.